Neurolink, Elon Mask’s sub-brain machine company, announced the completion of a round of E-finance of up to $650 million, which included a number of institutions such as Ark Investment, Founder Fund, Redwood Capital, Thrive Capital and Lightseed Venture Partners.
It was reported that the Neurolink valuation after the completion of the financing had exceeded $9 billion, further consolidating its leading position in the brain interface (BCI). This funding will give strong impetus to the company ‘ s future technological research and development, clinical trials and equipment roll-out, and will make the vision of human integration with artificial intelligence a reality.
This time, $650 million in financing was an important milestone in the development of Neuralink. In addition to the above-mentioned investment agencies, strong investors such as DFJ Growth, G42, Human Capital, QIA, Valor Equity Partners and Vy Capital are involved in this round.
Neuralink stated that the funds would help the company to scale up its manufacturing and engineering teams and lay a solid foundation for technology diffusion. To enable more patients in need to benefit from brain-engineer interface technology and to move technology from laboratory to practical application. Upgrade the functionality of the brain interface and enhance the connection between bio-intelligence and artificial intelligence.
The core product of Neuralink is the N1 implantation device, which records and stimulates brain neural signals through 1,024 electrodes (dispersed in 64 “wires” that are much smaller than human hair). This technology has been successfully applied to clinically to help severely paralysed patients control digital and physical equipment through their mind.
NeuralinkClinical trials are being conducted in several leading medical institutions around the world, including the Baro Institute of Neurology in the United States, the Miami Paralytic Recovery Project, the Western Hospital in Toronto, Canada, and the Abu Dhabi Cleveland Clinic.
In addition, Neuralink’s voice recovery equipment has been certified as “break-through equipment” by the United States Food and Drug Regulatory Authority (FDA) and the approval process is expected to be completed within 60 days, which will further accelerate the commercialization of the technology.
